NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA

OBJECTIVE: Refractory symptomatic plexiform neurofibromas (PNF) and inoperable refractory low grade gliomas (LGG) pose a clinical challenge that may be life threatening. Phase 1 and 2 clinical trials of MEK inhibition with selumetinib in inoperable PNF and LGG have demonstrated promising results in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hounjet, Celine D, Ronsley, Rebecca, Cheng, Sylvia, Rassekh, S Rod, Duncan, Walter J, Dunham, Christopher, Gardiner, Jane, Ghag, Arvindera, P, Ludemann, Jeffrey, Wensley, David, Rehmus, Wingfield, Sargent, Michael A, Evans, Naomi, Popovska, Vesna, Hukin, Juliette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Neurofibromatosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715867/
http://dx.doi.org/10.1093/neuonc/noaa222.615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715867/
http://dx.doi.org/10.1093/neuonc/noaa222.615

Ejemplares similares